Suit Claims Nutraceutical Corporation Falsely Labels Vitamin B12 Supplements
by Erin Shaak
Last Updated on May 8, 2018
Welk v. Nutraceutical Corporation
Filed: November 7, 2017 ◆§ 3:17-cv-02266-BEN-KSC
Nutraceutical Corporation is facing a proposed class action that claims it falsely advertises the amount of vitamin B12 in several of its supplement products.
California
Nutraceutical Corporation is facing a proposed class action that claims it falsely advertises the amount of vitamin B12 in several of its supplement products. The plaintiff alleges that the defendant (which the suit notes also does business under the names Biogenesis Nutraceuticals, Inc., Nutrabiogenesis, and Biogenesis) advertises that its products contain a certain amount of Methylcobalamin (MeCO) – a form of vitamin B12 that the complaint describes as less stable than other forms of the vitamin but more attractive to consumers. As soon as each product’s container is opened, however, the MeCO begins to degrade to the point that B12 levels become “negligible and ineffective,” according to the suit. The plaintiff claims that, as a result, the defendant’s products do not always contain the amount of vitamin B12 advertised on their labels and are therefore misleading.
The following products have been named in the lawsuit:
- BioGenesis —Methyl Factors 2 oz
- BioGenesis —Methyl Factors 2 oz (2,500 mcg of Methylcobalamin)
- LifeTime – Liquid B-Complex with Vitamin C
- Kal – B12 Methylcobalamin ActivSpray
- Kal – B12 ActiveSpray
- All Once – Liquid Life
Hair Relaxer Lawsuits
Women who developed ovarian or uterine cancer after using hair relaxers such as Dark & Lovely and Motions may now have an opportunity to take legal action.
Read more here: Hair Relaxer Cancer Lawsuits
How Do I Join a Class Action Lawsuit?
Did you know there's usually nothing you need to do to join, sign up for, or add your name to new class action lawsuits when they're initially filed?
Read more here: How Do I Join a Class Action Lawsuit?
Stay Current
Sign Up For
Our Newsletter
New cases and investigations, settlement deadlines, and news straight to your inbox.
Before commenting, please review our comment policy.